Glucose Biosensor Systems (Greater China) Holdings

General Information
Business:

 

Our biosensor technology is licensed from the Licensor, Life Science Biosensor Diagnostics Pty Ltd. This technology is patent protected and described in two granted patents: United States patent 9,766,199 and China patent ZL201380022888, both expiring year 2033. The Licensor is an Australian company that acquired all the intellectual property to the biosensor platform that relates to the life sciences, from the University of Newcastle, Australia, Center for Organic Electronics, or the “COE,” where the biosensor technology was invented and developed. The Licensor currently owns 99.6% of our outstanding common stock and will own a majority of our outstanding common stock immediately after this offering.

Our objective is to introduce and launch the Saliva Glucose Biosensor (referred to as the “SGB”), the first of our diagnostic tests that stem from the Biosensor Platform that we license, in the China Region.

 

Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees: 4
Founded: 2016
Contact Information
Address 708 Third Avenue, 6th Floor, New York, NY 10017, US
Phone Number (646) 790-5756
Web Address http://www.bdo.com.au
View Prospectus: Glucose Biosensor Systems (Greater China) Holdings
Financial Information
Market Cap
Revenues $0.11 mil (last 12 months)
Net Income $-4.15 mil (last 12 months)
IPO Profile
Symbol GBSG
Exchange NYSE
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $23.0 mil
Manager / Joint Managers Aegis Capital Corp.
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change